Literature DB >> 30554229

Irritable Bowel Syndrome-Like Symptoms in Ulcerative Colitis Patients in Clinical Remission: Association with Residual Colonic Inflammation.

Shunji Ishihara1,2, Kousaku Kawashima3,4, Nobuhiko Fukuba4, Yasumasa Tada4, Satoshi Kotani4, Yoshiyuki Mishima4, Naoki Oshima4, Yoshikazu Kinoshita4.   

Abstract

Ulcerative colitis (UC) patients in clinical remission often experience irritable bowel syndrome (IBS)-like symptoms. The prevalence rate of UC patients meeting the definition of IBS, such as shown by the Rome criteria, is significantly higher in those without ongoing clinical activity as compared to healthy controls. Several studies have investigated residual low-grade inflammation found in colonic mucosa of quiescent UC patients and its association with development of IBS-like symptoms. In these patients, residual colonic inflammation was evaluated using endoscopy and histology findings, as well as fecal calprotectin level and shown to not be simply associated with the presence of IBS-like symptoms in UC patients in clinical remission. However, these results are limited by the low number of related investigations conducted. Additional appropriately designed studies are necessary to confirm the relationship of low-grade colonic inflammation with IBS-like symptoms associated with UC.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Clinical remission; Endoscopic remission; Fecal calprotectin; Irritable bowel syndrome-like symptoms ; Ulcerative colitis

Mesh:

Year:  2018        PMID: 30554229     DOI: 10.1159/000494412

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Effects of propolis supplementation on irritable bowel syndrome with constipation (IBS-C) and mixed (IBS-M) stool pattern: A randomized, double-blind clinical trial.

Authors:  Mahsa Miryan; Davood Soleimani; Pejman Alavinejad; Mohammadreza Abbaspour; Alireza Ostadrahimi
Journal:  Food Sci Nutr       Date:  2022-04-20       Impact factor: 3.553

Review 2.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

3.  Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study.

Authors:  Kwangwoo Nam; Sang Hyoung Park; Jun Ho Oh; Ho-Su Lee; Soomin Noh; Jae Cheol Park; Jin Yong Kim; Eun Hye Oh; Jeongseok Kim; Nam Seok Ham; Sung Wook Hwang; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  BMC Gastroenterol       Date:  2021-01-06       Impact factor: 3.067

4.  A Pilot Study of Clinical Evaluation and Formation Mechanism of Irritable Bowel Syndrome-like Symptoms in Inflammatory Bowel Disease Patients in Remission.

Authors:  Haiyang Wang; Xiaojing Zhao; Xiufang Cui; Meifeng Wang; Chunhua Jiao; Jiajia Li; Yan Yang; Yi Li; Hongjie Zhang
Journal:  J Neurogastroenterol Motil       Date:  2021-10-30       Impact factor: 4.924

5.  The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis.

Authors:  Eun Ae Kang
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519

6.  Does propolis affect the quality of life and complications in subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded, placebo-controlled clinical trial.

Authors:  Mahsa Miryan; Pezhman Alavinejad; Mohammadreza Abbaspour; Davood Soleimani; Alireza Ostadrahimi
Journal:  Trials       Date:  2020-08-05       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.